Tickdelta is free for now. Sign up and get Pro free
4 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 25, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies: a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it. A paragraph most of them have is marked boilerplate. No line means no other company has one like it. This counts text; it does not say how serious a risk is.
•changes in trade policy applicable to the regions in which we do business, including changes in U.S. trade policies or the imposition of higher tariffs on products being shipped into and from the U.S.,
Read in the 10-K ↗
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole. AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business. Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings. Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services. The development of AI technology will require significant investment in resources and human capital and could increase our costs. There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection. Failure to comply or appropriately respond to this developing landscape may result in increased legal liability, adverse regulatory action, or reputational damage.
Read in the 10-K ↗
We cannot predict the scope, timing, or impact of threatened U.S. tariffs on imports, the extent to which other countries may impose retaliatory trade restrictions, or the terms of future trade policy changes. Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market. While we have implemented mitigation strategies including manufacturing optimization, supplier collaboration, pricing adjustments, and temporary cost measures, these actions may not fully offset the impact of existing or future tariffs. Additional tariffs or trade restrictions may materially and adversely affect our results of operations, financial condition, and competitive position.
Read in the 10-K ↗
5 paragraphs in the 10-Q filed Aug 11, 2026 with nothing like them in the 10-Q filed May 12, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
2026 2025 Operating activities: Net income $ 92,538 $ 96,185 Loss from discontinued operations, net of income taxes 1,836 706 Income from continuing operations 94,374 96,891 Adjustments to reconcile income from continuing operations to net cash provided by continuing operations: Stock-based compensation 19,446 17,864 Restructuring and other costs 46,183 14,442 Depreciation and amortization 207,095 200,200 Change in fair value of contingent consideration 1,527 (166) Amortization of deferred debt financing costs and accretion of discounts 2,440 2,320 Change in fair value of investments 9,455 (1,118) Unrealized foreign exchange loss 186 140 Gain on disposition of businesses and assets, net (5,074) — Changes in assets and liabilities which provided (used) cash: Accounts receivable, net 43,916 (21,901) Inventories (4,778) 5,642 Accounts payable (18,064) 3,278 Accrued expenses and other (78,876) (49,177) Net cash provided by operating activities of continuing operations 317,830 268,415 Net cash used in operating activities of discontinued operations (10,657) (5,942) Net cash provided by operating activities 307,173 262,473 Investing activities: Capital expenditures (30,848) (34,850) Purchases of investments and notes receivables (3,561) — Proceeds from investments and notes receivables 7,496 — Proceeds from disposition of property, plant and equipment 12,039 — Proceeds from disposition of businesses and assets 158 229 Cash paid for acquisitions, net of cash acquired (67,061) — Net cash used in investing activities of continuing operations (81,777) (34,621) Net cash provided by investing activities of discontinued operations — 18,750 Net cash used in investing activities (81,777) (15,871) Financing activities: Payments of debt financing issuance costs — (2,474) Payments of other credit facilities — (103) Payments for acquisition-related contingent consideration (350) (1,978) Proceeds from issuance of common stock under stock plans 6,437 2,632 Purchases of common stock (102,488) (447,501) Dividends paid (15,654) (16,715) Net cash used in financing activities (112,055) (466,139)
Read in the 10-Q ↗
In July 2026, the Company repaid upon maturity all of its outstanding 2026 Notes at an aggregate principal amount of € 500.0 million ($ 571.2 million).
Read in the 10-Q ↗
In the second quarter of fiscal years 2026 and 2025, the Company paid $ 8.0 million and $ 3.2 million in excise taxes related to the 2025 and 2024 share repurchases, respectively. Amounts paid for excise taxes on share repurchases are included in financing activities in the accompanying consolidated condensed statements of cash flows.
Read in the 10-Q ↗
On July 31, 2026, the Company entered into a definitive agreement to divest its Immunodiagnostics business in China, which represented approximately 6% of the Company’s total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals.
Read in the 10-Q ↗
difficult global financial markets, we may be forced to fund our operations at a higher cost, or we may be unable to raise as much funding as we need to support our business activities or fund our strategic transactions.
Read in the 10-Q ↗
Item 1A of the 10-Q filed Aug 11, 2026 against Item 1A of the 10-K filed Feb 24, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted and underlined).
Text on the page, not a score; each links to the filing at sec.gov.
